Cogent Biosciences, Inc. — Q1 2023 Form 10-Q
Business context and reporting period
Cogent is a clinical-stage biotechnology company developing precision medicines for genetically defined diseases. This unaudited report covers the three months ended March 31, 2023. Its lead candidate, bezuclastinib, is being developed for systemic mastocytosis and gastrointestinal stromal tumors (GIST); the company also has preclinical FGFR2 and ErbB2 programs. Cogent reported no product revenue and has no approved products.
Financial performance and position
| Metric | Q1 2023 | Q1 2022 or comparison |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $36.0 million | $25.5 million |
| General and administrative expense | $7.2 million | $5.9 million |
| Total operating expenses / operating loss | $43.2 million | $31.4 million |
| Net loss | $38.6 million | $30.6 million |
| Net loss per share, basic and diluted | $0.55 | $0.68 |
| Cash used in operating activities | $39.5 million | $28.3 million |
Gross margin is not applicable because Cogent reported no product revenue. Operating expenses rose 38% year over year, with R&D up $10.6 million, mainly from bezuclastinib trials and manufacturing, pipeline research, personnel, and research facilities. Net loss increased $8.0 million; the lower loss per share reflects a substantially higher weighted-average share count. Stock-based compensation was $5.9 million.
At March 31, cash and cash equivalents were $160.7 million and marketable securities were $59.6 million, totaling $220.3 million; restricted cash was an additional $1.3 million. Total liabilities were $39.6 million, including $19.5 million of operating lease liabilities. The balance sheet lists no borrowings. Accumulated deficit was $449.8 million. Investing activities provided $59.9 million, primarily reflecting marketable-security maturities and sales; this was not operating cash generation.
Material changes versus the prior comparable period
- R&D expense increased 42%, and G&A expense increased 21%, driving higher operating expenses and net loss.
- Interest income rose to $2.3 million from $0.1 million, reflecting higher invested balances. A $1.7 million gain from reducing the estimated contingent value right (CVR) liability to zero also increased reported other income; this was a fair-value adjustment, not recurring operating revenue.
- Operating cash use increased by $11.2 million. Cash, cash equivalents, and marketable securities totaled $220.3 million at quarter-end, versus $259.3 million at December 31, 2022.
- Common shares outstanding increased to 70.9 million from 69.9 million at year-end. Separately, Series A preferred shares outstanding were convertible into 19.3 million common shares; 606,060 pre-funded warrants also remained outstanding.
Outlook, commentary, risks, and unusual items
- Management estimated that quarter-end cash, cash equivalents, and marketable securities would fund operating expenses and capital requirements into 2025. The filing also cautions that this estimate depends on assumptions, that funds could be exhausted sooner, and that additional funding will be required to complete planned research and development.
- Cogent expects expenses and operating losses to continue and increase. It may seek capital through equity or debt offerings, collaborations, licensing, and other arrangements; financing could dilute shareholders, impose restrictions, or require relinquishing rights.
- Clinical plans: APEX Part 2 began in April 2023 with an optimized bezuclastinib formulation; APEX data from about 30 Part 1 patients were expected in the second half of 2023. Initial SUMMIT data were also expected in the second half of 2023. Updated PEAK lead-in data were expected at ASCO in June 2023. Clinical trials for the FGFR2 and ErbB2 programs were expected to begin in 2024. These are forward-looking expectations, not guaranteed outcomes.
- Key risks include clinical safety, efficacy and enrollment; regulatory review and approval; manufacturing and supply; competition; intellectual-property protection; and access to additional capital. The company reported no material legal proceedings and no material changes to the risk factors in its 2022 Form 10-K.
- The $1.7 million Q1 CVR fair-value gain reflects management’s reduced likelihood of further payments before the CVR expires in July 2023. The estimate relies on significant unobservable inputs.
Important facts for investors to verify
- Whether the cash runway estimate into 2025 remains reasonable as trial enrollment, manufacturing, and research spending evolve.
- Clinical progress, safety, efficacy, and timing of APEX, SUMMIT, and PEAK updates, as well as the planned 2024 FGFR2 and ErbB2 trial starts.
- Potential dilution from future financing and the conversion of preferred shares or exercise of warrants.
- Whether the CVR is fully settled or expires without further payment, and whether any change in its valuation affects reported earnings.